Top

Current Treatment Options in Gastroenterology

Published in:

01-09-2020 | Endoscopy | Stomach (P Malfertheiner, Section Editor)

Gastritis: An Update in 2020

Authors: Massimo Rugge, MD, Kentaro Sugano, Diana Sacchi, Marta Sbaraglia, Peter Malfertheiner

Published in: Current Treatment Options in Gastroenterology | Issue 3/2020

Abstract

Purpose of review

The gastritis constellation includes heterogeneous clinicopathological entities, among which long-standing, non-self-limiting gastritis, mainly due to Helicobacter pylori infection, has been epidemiologically, biologically, and clinically linked to gastric cancer development (i.e. “inflammation-associated cancer”). This review illustrates the updated criteria applied in the taxonomy of gastritis (Kyoto classification), elucidates the biological rationale for endoscopy biopsy sampling (heterogeneity of gastric mucosa), and finally reports the results of long-term follow-up studies supporting the reliability of biopsy-based gastritis staging as predictor of gastritis-associated cancer risk.

Recent findings

By assuming gastric atrophy as the “cancerization field” where (non-syndromic) gastric cancer mostly develops, recent long-term follow-up studies consistently demonstrate the prognostic impact of the gastritis OLGA staging system.

Summary

Helicobacter pylori eradication is the leading strategy in the primary prevention of gastric cancer. In a multidisciplinary dimension of secondary cancer prevention, the OLGA staging system reliably ranks the patient-specific cancer risk, thus providing the clinical rationale for a tailored follow-up strategy.

Talley NJ. Editorial: moving away from focussing on gastric pathophysiology in functional dyspepsia: new insights and therapeutic implications. Am J Gastroenterol. 2017;112(1):141–4. https://doi.org/10.1038/ajg.2016.519.PubMedCrossRef

Miwa H, Oshima T, Tomita T, et al. Recent understanding of the pathophysiology of functional dyspepsia: role of the duodenum as the pathogenic center. J Gastroenterol. 2019;54(4):305–11. https://doi.org/10.1007/s00535-019-01550-4.PubMedPubMedCentralCrossRef

Okamura T, Iwaya Y, Kitahara K, Suga T, Tanaka E. Accuracy of endoscopic diagnosis for mild atrophic gastritis infected with Helicobacter pylori. Clin Endosc. 2018;51(4):362–7. https://doi.org/10.5946/ce.2017.177.PubMedPubMedCentralCrossRef

Fukuda H, Miura Y, Osawa H, et al. Linked color imaging can enhance recognition of early gastric cancer by high color contrast to surrounding gastric intestinal metaplasia. J Gastroenterol. 2019;54(5):396–406. https://doi.org/10.1007/s00535-018-1515-6.PubMedCrossRef

Takeda T, Asaoka D, Nojiri S, et al. Linked color imaging and the Kyoto classification of gastritis: evaluation of visibility and inter-Rater reliability. Digestion. 2019:1–10. https://doi.org/10.1159/000501534.

Sun X, Bi Y, Nong B, et al. Linked color imaging confers benefits in profiling H. pylori infection in the stomach. Endosc Int open. 2019;7(7):E885–92. https://doi.org/10.1055/a-0895-5377.PubMedPubMedCentralCrossRef

Dohi O, Majima A, Naito Y, et al. Can image-enhanced endoscopy improve the diagnosis of Kyoto classification of gastritis in the clinical setting? Dig Endosc. 2019:den.13540. https://doi.org/10.1111/den.13540.

Rugge M, Fassan M, Tsukanov VV, Meggio A, de Boni M. From open-type atrophic gastritis to gastritis staging. Dig Dis Sci. 2011;56(6):1917–8. https://doi.org/10.1007/s10620-011-1705-z.PubMedCrossRef

Mizukami K, Ogawa R, Okamoto K, et al. Objective endoscopic analysis with linked color imaging regarding gastric mucosal atrophy: a pilot study. Gastroenterol Res Pract. 2017;2017:5054237. https://doi.org/10.1155/2017/5054237.PubMedPubMedCentralCrossRef

10.

White JR, Sami SS, Reddiar D, et al. Narrow band imaging and serology in the assessment of premalignant gastric pathology. Scand J Gastroenterol. 2018;53(12):1611–8. https://doi.org/10.1080/00365521.2018.1542455.PubMedCrossRef

11.

•• Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353–67. https://doi.org/10.1136/gutjnl-2015-309252. The publication refers the results of a global consensus concerning the taxonomy of gastritis.PubMedCrossRef

12.

Mahachai V, Vilaichone R-K, Pittayanon R, et al. Helicobacter pylori management in ASEAN: the Bangkok consensus report. J Gastroenterol Hepatol. 2018;33(1):37–56. https://doi.org/10.1111/jgh.13911.PubMedCrossRef

13.

Rugge M, Sugano K, Scarpignato C, Sacchi D, Oblitas WJ, Naccarato AG. Gastric cancer prevention targeted on risk assessment: gastritis OLGA staging. Helicobacter. 2019;24(2):e12571. https://doi.org/10.1111/hel.12571.PubMedCrossRef

14.

Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease. Gut. 2015;64(10):1650–68. https://doi.org/10.1136/gutjnl-2014-307595.PubMedCrossRef

15.

El-Zimaity H, Choi W-T, Lauwers GY, Riddell R. The differential diagnosis of Helicobacter pylori negative gastritis. Virchows Arch. 2018;473(5):533–50. https://doi.org/10.1007/s00428-018-2454-6.PubMedCrossRef

16.

Choi W-T, Lauwers GY. Patterns of gastric injury: beyond Helicobacter pylori. Surg Pathol Clin. 2017;10(4):801–22. https://doi.org/10.1016/j.path.2017.07.003.PubMedCrossRef

17.

Weinstein R, Riordan MA, Wenc K, Kreczko S, Zhou M, Dainiak N. Dual role of fibronectin in hematopoietic differentiation. Blood. 1989;73(1):111–6. http://www.ncbi.nlm.nih.gov/pubmed/2910353. Accessed 19 Nov 2019.PubMedCrossRef

18.

Nordenstedt H, Graham DY, Kramer JR, et al. Helicobacter pylori-negative gastritis: prevalence and risk factors. Am J Gastroenterol. 2013;108(1):65–71. https://doi.org/10.1038/ajg.2012.372.PubMedCrossRef

19.

Shiota S, Thrift AP, Green L, et al. Clinical manifestations of Helicobacter pylori-negative gastritis. Clin Gastroenterol Hepatol. 2017;15(7):1037–1046.e3. https://doi.org/10.1016/j.cgh.2017.01.006.PubMedCrossRef

20.

• Rugge M, Genta RM, Di Mario F, et al. Gastric cancer as preventable disease. Clin Gastroenterol Hepatol. 2017;15(12):1833–43. https://doi.org/10.1016/j.cgh.2017.05.023. This comprehensive review provides the biological and clinical rationale for gastric cancer prevention strategies.PubMedCrossRef

21.

Ruiz B, Garay J, Johnson W, et al. Morphometric assessment of gastric antral atrophy: comparison with visual evaluation. Histopathology. 2001;39(3):235–42. https://doi.org/10.1046/j.1365-2559.2001.01221.x.PubMedCrossRef

22.

Rugge M, Correa P, Dixon MF, et al. Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading. Aliment Pharmacol Ther. 2002;16(7):1249–59. https://doi.org/10.1046/j.1365-2036.2002.01301.x.PubMedCrossRef

23.

Zambon C-F, Basso D, Navaglia F, et al. Helicobacter pylori virulence genes and host IL-1RN and IL-1beta genes interplay in favouring the development of peptic ulcer and intestinal metaplasia. Cytokine. 2002;18(5):242–51. https://doi.org/10.1006/cyto.2002.0891.PubMedCrossRef

24.

Graham DY, Rugge M, Genta RM. Diagnosis: gastric intestinal metaplasia – what to do next? Curr Opin Gastroenterol. 2019;35(6):535–43. https://doi.org/10.1097/MOG.0000000000000576.PubMedCrossRefPubMedCentral

25.

Goldenring JR. Pyloric metaplasia, pseudopyloric metaplasia, ulcer-associated cell lineage and spasmolytic polypeptide-expressing metaplasia: reparative lineages in the gastrointestinal mucosa. J Pathol. 2018;245(2):132–7. https://doi.org/10.1002/path.5066.PubMedPubMedCentralCrossRef

26.

Radyk MD, Burclaff J, Willet SG, Mills JC. Metaplastic cells in the stomach arise, independently of stem cells, via dedifferentiation or transdifferentiation of chief cells. Gastroenterology. 2018;154(4):839–843.e2. https://doi.org/10.1053/j.gastro.2017.11.278.PubMedCrossRef

27.

Hayakawa Y, Ariyama H, Stancikova J, et al. Mist1 expressing gastric stem cells maintain the normal and neoplastic gastric epithelium and are supported by a perivascular stem cell niche. Cancer Cell. 2015;28(6):800–14. https://doi.org/10.1016/j.ccell.2015.10.003.PubMedPubMedCentralCrossRef

28.

Hayakawa Y, Fox JG, Wang TC. Isthmus stem cells are the origins of metaplasia in the gastric corpus. Cell Mol Gastroenterol Hepatol. 2017;4(1):89–94. https://doi.org/10.1016/j.jcmgh.2017.02.009.PubMedPubMedCentralCrossRef

29.

Rugge M, Pennelli G, Pilozzi E, et al. Gastritis: the histology report. Dig Liver Dis. 2011;43(Suppl 4):S373–84. https://doi.org/10.1016/S1590-8658(11)60593-8.PubMedCrossRef

30.

Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40(8):650–8. https://doi.org/10.1016/j.dld.2008.02.030.PubMedCrossRef

31.

Parsons BN, Ijaz UZ, D’Amore R, et al. Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use. PLoS Pathog. 2017;13(11):e1006653. https://doi.org/10.1371/journal.ppat.1006653.PubMedPubMedCentralCrossRef

32.

Badal VD, Wright D, Katsis Y, et al. Challenges in the construction of knowledge bases for human microbiome-disease associations. Microbiome. 2019;7(1):129. https://doi.org/10.1186/s40168-019-0742-2.PubMedPubMedCentralCrossRef

33.

Park CH, Lee A-R, Lee Y-R, Eun CS, Lee SK, Han DS. Evaluation of gastric microbiome and metagenomic function in patients with intestinal metaplasia using 16S rRNA gene sequencing. Helicobacter. 2019;24(1):e12547. https://doi.org/10.1111/hel.12547.PubMedCrossRef

34.

Del Prete A, Allavena P, Santoro G, Fumarulo R, Corsi MM, Mantovani A. Molecular pathways in cancer-related inflammation. Biochem Medica. 2011:264–75. https://doi.org/10.11613/BM.2011.036.

35.

Iino C, Shimoyama T, Chinda D, Sakuraba H, Fukuda S, Nakaji S. Influence of Helicobacter pylori infection and atrophic gastritis on the gut microbiota in a Japanese population. Digestion. 2019:1–11. https://doi.org/10.1159/000500634.

36.

McDonald SAC, Greaves LC, Gutierrez-Gonzalez L, et al. Mechanisms of field cancerization in the human stomach: the expansion and spread of mutated gastric stem cells. Gastroenterology. 2008;134(2):500–10. https://doi.org/10.1053/j.gastro.2007.11.035.PubMedCrossRef

37.

McCracken KW, Wells JM. Mechanisms of embryonic stomach development. Semin Cell Dev Biol. 2017;66:36–42. https://doi.org/10.1016/j.semcdb.2017.02.004.PubMedPubMedCentralCrossRef

38.

Thompson CA, DeLaForest A, Battle MA. Patterning the gastrointestinal epithelium to confer regional-specific functions. Dev Biol. 2018;435(2):97–108. https://doi.org/10.1016/j.ydbio.2018.01.006.PubMedPubMedCentralCrossRef

39.

Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30. https://doi.org/10.1136/gutjnl-2016-312288.PubMedCrossRef

40.

• Rugge M, Genta RM, Fassan M, et al. OLGA gastritis staging for the prediction of gastric cancer risk: a long-term follow-up study of 7436 patients. Am J Gastroenterol. 2018;113(11):1621–8. https://doi.org/10.1038/s41395-018-0353-8. In this long-term follow-up study of 7436 patients, a significant increased risk of gastric cancer was only associated with patients harbouring OLGA stages III/IV at their enrollment.PubMedCrossRef

41.

Rugge M, Sacchi D, Graham DY, Genta RM. Secondary prevention of gastric cancer: merging the endoscopic atrophic border with OLGA staging. Gut. 2019:gutjnl-2019-319107. https://doi.org/10.1136/gutjnl-2019-319107.

42.

Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365–88. https://doi.org/10.1055/a-0859-1883.PubMedCrossRef

43.

Kono S, Gotoda T, Yoshida S, et al. Can endoscopic atrophy predict histological atrophy? Historical study in United Kingdom and Japan. World J Gastroenterol. 2015;21(46):13113–23. https://doi.org/10.3748/wjg.v21.i46.13113.PubMedPubMedCentralCrossRef

44.

Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;1(03):87–97. https://doi.org/10.1055/s-0028-1098086.CrossRef

45.

Price AB. The Sydney system: histological division. J Gastroenterol Hepatol. 1991;6(3):209–22. https://doi.org/10.1111/j.1440-1746.1991.tb01468.x.PubMedCrossRef

46.

Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56(5):631–6. https://doi.org/10.1136/gut.2006.106666.PubMedCrossRef

47.

Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71(7):1150–8. https://doi.org/10.1016/j.gie.2009.12.029.PubMedCrossRef

48.

Rugge M, Fassan M, Pizzi M, et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol. 2011;17(41):4596–601. https://doi.org/10.3748/wjg.v17.i41.4596.PubMedPubMedCentralCrossRef

49.

Meggio A, Mariotti G, Gentilini M, de Pretis G. Priority and appropriateness of upper endoscopy out-patient referrals: two-period comparison in an open-access unit. Dig Liver Dis. 2019;51(11):1562–6. https://doi.org/10.1016/j.dld.2019.05.028.PubMedCrossRef

50.

Teriaky A, AlNasser A, McLean C, Gregor J, Yan B. The utility of endoscopic biopsies in patients with normal upper endoscopy. Can J Gastroenterol Hepatol. 2016;2016:3026563. https://doi.org/10.1155/2016/3026563.PubMedPubMedCentralCrossRef

51.

Schulz C, Schütte K, Koch N, et al. The active bacterial assemblages of the upper GI tract in individuals with and without Helicobacter infection. Gut. 2018;67(2):216–25. https://doi.org/10.1136/gutjnl-2016-312904.PubMedCrossRef

52.

Fallone CA, Moss SF, Malfertheiner P. Reconciliation of recent Helicobacter pylori treatment guidelines in a time of increasing resistance to antibiotics. Gastroenterology. 2019;157(1):44–53. https://doi.org/10.1053/j.gastro.2019.04.011.PubMedCrossRef

53.

•• Malfertheiner P. Diagnostic methods for H. pylori infection: choices, opportunities and pitfalls. United Eur Gastroenterol J. 2015;3(5):429–31. https://doi.org/10.1177/2050640615600968. The review critically considers the different (non-invasive and invasive) methods clinically applied in the assessment of current Helicobacer pylori infection.CrossRef

54.

Jeffries GH, Todd JE, Sleisenger MH. The effect of prednisolone on gastric mucosal histology, gastric secretion, and vitamin B 12 absorption in patients with pernicious anemia. J Clin Invest. 1966;45(5):803–12. https://doi.org/10.1172/JCI105395.PubMedPubMedCentralCrossRef

55.

Zhang M, Liu S, Hu Y, et al. Biopsy strategies for endoscopic screening of pre-malignant gastric lesions. Sci Rep. 2019;9(1):14909. https://doi.org/10.1038/s41598-019-51487-0.PubMedPubMedCentralCrossRef

56.

Isajevs S, Liepniece-Karele I, Janciauskas D, et al. Gastritis staging: interobserver agreement by applying OLGA and OLGIM systems. Virchows Arch. 2014;464(4):403–7. https://doi.org/10.1007/s00428-014-1544-3.PubMedCrossRef

57.

Halldórsdóttir AM, Sigurdardóttrir M, Jónasson JG, et al. Spasmolytic polypeptide-expressing metaplasia (SPEM) associated with gastric cancer in Iceland. Dig Dis Sci. 2003;48(3):431–41. https://doi.org/10.1023/a:1022564027468.PubMedCrossRef

58.

Koulis A, Buckle A, Boussioutas A. Premalignant lesions and gastric cancer: current understanding. World J Gastrointest Oncol. 2019;11(9):665–78. https://doi.org/10.4251/wjgo.v11.i9.665.PubMedPubMedCentralCrossRef

59.

Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019:his.13975. https://doi.org/10.1111/his.13975.

60.

Rugge M, de Boni M, Pennelli G, et al. Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study. Aliment Pharmacol Ther. 2010;31(10):1104–11. https://doi.org/10.1111/j.1365-2036.2010.04277.x.PubMedCrossRef

61.

•• Rugge M, Meggio A, Pravadelli C, et al. Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut. 2019;68(1):11–7. https://doi.org/10.1136/gutjnl-2017-314600. In a large cohort of 1755 dyspeptic outpatients undergoing upper gastrointestinal endoscopy, this long-term follow-up study provides evidence that a significant risk of neoplastic progression is only associated with patients harboring OLGA stages III/IV at their enrollment.PubMedCrossRef

62.

de Vries AC, Kuipers EJ, Rauws EAJ. Helicobacter pylori eradication and gastric cancer: when is the horse out of the barn? Am J Gastroenterol. 2009;104(6):1342–5. https://doi.org/10.1038/ajg.2008.15.PubMedCrossRef

63.

Rugge M, de Boni M, Pennelli G, Mescoli C, Graham DY. OLGA can guard the barn. Am J Gastroenterol. 2009;104(12):3099. author reply 3101-2. https://doi.org/10.1038/ajg.2009.512.PubMedCrossRef

64.

Genta RM, Rugge M. Gastric precancerous lesions: heading for an international consensus. Gut. 1999;45(Suppl 1):I5–8. http://www.ncbi.nlm.nih.gov/pubmed/10457028.PubMedPubMedCentralCrossRef

65.

Choi IJ, Kim Y-I, Park B. Helicobacter pylori and prevention of gastric cancer. N Engl J Med. 2018;378(23):2244–5. https://doi.org/10.1056/NEJMc1805129.PubMedCrossRef

Title: Gastritis: An Update in 2020
Authors: Massimo Rugge, MD
Kentaro Sugano
Diana Sacchi
Marta Sbaraglia
Peter Malfertheiner
Publication date: 01-09-2020
Publisher: Springer US
Keywords: Endoscopy
Helicobacter Pylori
Gastritis
Gastric Cancer
Gastric Cancer
Published in: Current Treatment Options in Gastroenterology / Issue 3/2020
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI: https://doi.org/10.1007/s11938-020-00298-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of review

Recent findings

Summary

Please log in to get access to this content

Other articles of this Issue 3/2020

Novel Therapeutics for the Treatment of IBD: Current Status and Future Directions

Update on Pregnancy in Patients with IBD

Inflammatory Bowel Disease Therapy and Venous Thromboembolism

7RECENT Advances in Endoscopic Treatments for Gastroesophageal Reflux Disease

Update on the Management of Helicobacter pylori Infection

What Is the Optimal Surveillance Strategy for Non-dysplastic Barrett’s Esophagus?

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage